Glenmark Receives US FDA Approval for RYALTRIS Expansion; Shares Trade Lower

Mumbai July, 21: Glenmark Pharmaceuticals Ltd. has received approval from the US Food and Drug Administration (FDA) to expand the use of its allergy nasal spray RYALTRIS to children aged 6 years to under 12 years, widening the drug’s eligible patient population in the United States.

The approval covers the treatment of Seasonal Allergic Rhinitis (SAR) in younger paediatric patients. Until now, RYALTRIS was approved in the US for adults and children aged 12 years and above. With the latest clearance, the therapy can now be prescribed to patients aged six years and older.

The expanded indication is backed by a Phase 3, randomized, double-blind, placebo-controlled study involving 446 children between the ages of six and 11. According to the company, the trial showed that RYALTRIS improved nasal allergy symptoms compared with placebo and was well tolerated during the 14-day treatment period.

Glenmark said the approval comes at a time when it has transitioned to direct commercialization of RYALTRIS in the US. From April 1, 2026, its US subsidiary assumed full responsibility for the product’s marketing, distribution and customer engagement, giving the company greater control over the brand’s commercial strategy.

The company also noted that RYALTRIS is now approved across several international markets, including the European Union, the United Kingdom, Australia, South Korea, Russia and China. During FY26, the product was launched in 11 additional markets, taking its global presence to 56 countries.

Glenmark Share Price Remains Under Pressure

Despite the regulatory milestone, investor reaction remained muted.

Glenmark share price was trading at ₹2,234.30, down 0.23%, as of 11:31 AM IST on July 21. The stock moved in a narrow range through the morning session, indicating that the FDA approval had little immediate impact on trading sentiment.

While regulatory approvals are generally viewed positively because they expand a drug’s addressable market, investors often look for clarity on commercial potential and revenue contribution before reassessing valuations.

Company Background

Glenmark Pharmaceuticals is a global research-driven pharmaceutical company with operations across branded, generic and specialty medicines. It has a presence in more than 80 countries and focuses on therapeutic areas including respiratory, dermatology and oncology.

RYALTRIS is a fixed-dose nasal spray combining olopatadine hydrochloride, an antihistamine, and mometasone furoate, a corticosteroid, for the treatment of seasonal allergic rhinitis.

Conclusion

The latest FDA approval extends RYALTRIS to a younger patient group and strengthens Glenmark’s respiratory portfolio in the US, where the company now directly commercializes the product. While the development broadens the medicine’s long-term market opportunity, the stock was little changed during Tuesday’s trading session, suggesting investors are waiting for the approval to translate into measurable commercial gains.

Source:

• https://www.nseindia.com/get-quote/equity/GLENMARK/Glenmark-Pharmaceuticals-Limited
• https://nsearchives.nseindia.com/corporate/GLENMARK_21072026084047_BSE_NSE_21072026_signed.pdf